HUTCHMED (China) Limited
HCM
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastriā¦ read more
Healthcare
Drug ManufacturersāSpecialty & Generic
10 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$13.12
Price-3.32%
-$0.45
1Y
Price
Market Cap
$2.289b
Mid
Price/Earnings 3y Avg5y Avg
4.9x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+2.9%
EBITDA Margin+5.7%
Net Profit Margin+2.4%
Free Cash Flow Margin+2.9%
EBITDA Margin+5.7%
Net Profit Margin+2.4%
Free Cash Flow MarginRevenue
$549.122m
-0.1%
1y CAGR-12.6%
3y CAGR+14.7%
5y CAGREarnings
$17.883m
-96.1%
1y CAGR+318.5%
3y CAGR+270.9%
5y CAGREPS
$0.10
-96.1%
1y CAGR+307.5%
3y CAGR+262.6%
5y CAGRBook Value
$1.275b
$1.736b
Assets$461.459m
Liabilities$94.508m
DebtDebt to Assets
5.4%
-4.6x
Debt to EBITDAFree Cash Flow
$9.949m
+111.2%
1y CAGR-135.8%
3y CAGR-61.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company